Vitronectin dictates intraglomerular fibrinolysis in immune-mediated glomerulonephritis

FASEB Journal

Volumn 25, Issue 10, 2011, Pages 3543-3553

  Mesnard, Laurent ^a,b   Rafat, Cédric ^a,b   Vandermeersch, Sophie ^a   Hertig, Alexandre ^a,b   Cathelin, Dominique ^a   Xu Dubois, Yi Chun ^a   Jouanneau, Chantal ^a   Keller, Alexandre Castro ^c,d   Ribeil, Jean Antoine ^c   Leite de Moraes, Maria C ^c   Rondeau, Eric ^a,b  

^a HÔPITAL TENON   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Complement system; Kidney; Mouse model; PAI 1

Indexed keywords

COMPLEMENT COMPONENT C3; FIBRIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; FIBRIN DEPOSITION; FIBRINOLYSIS; IMMUNE COMPLEX NEPHRITIS; KIDNEY FAILURE; MOUSE; NEPHROTOXICITY; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEINURIA;

ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; GENE EXPRESSION REGULATION; GLOMERULAR BASEMENT MEMBRANE; GLOMERULONEPHRITIS; IMMUNOGLOBULIN G; MICE; MICE, KNOCKOUT; RENAL INSUFFICIENCY; SERPIN E2; VITRONECTIN;

MUS;

EID: 80053922244     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.11-180752     Document Type: Article

References (48)

1. Vassalli, P., and McCluskey, R. T. (1964) The pathogenic role of fibrin deposition in immunologically induced glomerulonephritis. Ann. N. Y. Acad. Sci. 116, 1052-1062
2. Wardle, E. N. (1974) Fibrin in renal disease: functional considerations. Clin. Nephrol. 2, 85-92
3. Drew, A. F., Tucker, H. L., Liu, H., Witte, D. P., Degen, J. L., and Tipping, P. G. (2001) Crescentic glomerulonephritis is diminished in fibrinogen-deficient mice. Am. J. Physiol. Renal Physiol. 281, F1157-F1163
4. Hertig, A., and Rondeau, E. (2004) Role of the coagulation/fibrinolysis system in fibrin-associated glomerular injury. J. Am. Soc. Nephrol. 15, 844-853 (Pubitemid 38375303)
5. Rondeau, E., Mougenot, B., Lacave, R., Peraldi, M. N., Kruithof, E. K., and Sraer, J. D. (1990) Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies. Clin. Nephrol. 33, 55-60 (Pubitemid 20058510)
6. Giroux, L., Verroust, P., Morel-Maroger, L., Delarue, F., Delauche, M., and Sraer, J. D. (1979) Glomerular fibrinolytic activity during nephrotoxic nephritis. Lab. Invest. 40, 415-422 (Pubitemid 9172191)
7. Kitching, A. R., Holdsworth, S. R., Ploplis, V. A., Plow, E. F., Collen, D., Carmeliet, P., and Tipping, P. G. (1997) Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J. Exp. Med. 185, 963-968 (Pubitemid 27119880)
8. Kitching, A. R., Kong, Y. Z., Huang, X. R., Davenport, P., Edgtton, K. L., Carmeliet, P., Holdsworth, S. R., and Tipping, P. G. (2003) Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis. J. Am. Soc. Nephrol. 14, 1487-1495 (Pubitemid 36687050)
9. Preissner, K. T. (1991) Structure and biological role of vitronectin. Annu. Rev. Cell Biol. 7, 275-310
10. Seiffert, D. (1997) Constitutive and regulated expression of vitronectin. Histol. Histopathol. 12, 787-797
11. Schvartz, I., Seger, D., and Shaltiel, S. (1999) Vitronectin. Int. J. Biochem. Cell Biol. 31, 539-544 (Pubitemid 29219400)
12. Tomasini, B. R., and Mosher, D. F. (1991) Vitronectin. Prog. Hemost. Thromb. 10, 269-305
13. Arroyo De Prada, N., Schroeck, F., Sinner, E. K., Muehlenweg, B., Twellmeyer, J., Sperl, S., Wilhelm, O. G., Schmitt, M., and Magdolen, V. (2002) Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin. Eur. J. Biochem. 269, 184-192
14. Zhou, A., Huntington, J. A., Pannu, N. S., Carrell, R. W., and Read, R. J. (2003) How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat. Struct. Biol. 10, 541-544 (Pubitemid 36792905)
15. Podor, T. J., Joshua, P., Butcher, M., Seiffert, D., Loskutoff, D., and Gauldie, J. (1992) Accumulation of type 1 plasminogen activator inhibitor and vitronectin at sites of cellular necrosis and inflammation. Ann. N. Y. Acad. Sci. 667, 173-177 (Pubitemid 23061575)
16. Podor, T. J., Campbell, S., Chindemi, P., Foulon, D. M., Farrell, D. H., Walton, P. D., Weitz, J. I., and Peterson, C. B. (2002) Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma a/gamma ' fibrinogen. J. Biol. Chem. 277, 7520-7528 (Pubitemid 34953150)
17. Zheng, X., Saunders, T. L., Camper, S. A., Samuelson, L. C., and Ginsburg, D. (1995) Vitronectin is not essential for normal mammalian development and fertility. Proc. Natl. Acad. Sci. U. S. A. 92, 12426-12430 (Pubitemid 26014082)
18. Preissner, K. T., de Boer, H., Pannekoek, H., and de Groot, P. G. (1996) Thrombin regulation by physiological inhibitors: the role of vitronectin. Semin. Thromb. Hemost. 22, 165-172 (Pubitemid 26239910)
19. Stoop, A. A., Lupu, F., and Pannekoek, H. (2000) Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes. Arterioscler. Thromb. Vasc. Biol. 20, 1143-1149 (Pubitemid 30207594)
20. Bariety, J., Hinglais, N., Bhakdi, S., Mandet, C., Rouchon, M., and Kazatchkine, M. D. (1989) Immunohistochemical study of complement S protein (Vitronectin) in normal and diseased human kidneys: relationship to neoantigens of the C5b-9 terminal complex. Clin. Exp. Immunol. 75, 76-81 (Pubitemid 19058778)
21. Turnberg, D., Botto, M., Warren, J., Morgan, B. P., Walport, M. J., and Cook, H. T. (2003) CD59a deficiency exacerbates accelerated nephrotoxic nephritis in mice. J. Am. Soc. Nephrol. 14, 2271-2279 (Pubitemid 37052373)
22. Hertig, A., Berrou, J., Allory, Y., Breton, L., Commo, F., Costa De Beauregard, M. A., Carmeliet, P., and Rondeau, E. (2003) Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. FASEB J. 17, 1904-1906
23. Lin, F., Salant, D. J., Meyerson, H., Emancipator, S., Morgan, B. P., and Medof, M. E. (2004) Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis. J. Immunol. 172, 2636-2642 (Pubitemid 38185803)
24. Mesnard, L., Keller, A. C., Michel, M. L., Vandermeersch, S., Rafat, C., Letavernier, E., Tillet, Y., Rondeau, E., and Leite-de-Moraes, M. C. (2009) Invariant natural killer T cells and TGF-βattenuate anti-GBM glomerulonephritis. J. Am. Soc. Nephrol. 20, 1282-1292
25. Salant, D. J., and Cybulsky, A. V. (1988) Experimental glomerulonephritis. Methods Enzymol. 162, 421-461 (Pubitemid 19019528)
26. Lloyd, C. M., Minto, A. W., Dorf, M. E., Proudfoot, A., Wells, T. N., Salant, D. J., and Gutierrez-Ramos, J. C. (1997) RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J. Exp. Med. 185, 1371-1380 (Pubitemid 27172917)
27. Morley, A. R., and Wheeler, J. (1985) Cell proliferation within Bowman's capsule in mice. J. Pathol. 145, 315-327 (Pubitemid 15033385)
28. Tüzün, E., Scott, B. G., Goluszko, E., Higgs, S., and Christadoss, P. (2003) Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J. Immunol. 171, 3847-3854 (Pubitemid 37264927)
29. Huang, Y., Haraguchi, M., Lawrence, D. A., Border, W. A., Yu, L., and Noble, N. A. (2003) A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J. Clin. Invest. 112, 379-388 (Pubitemid 38063766)
30. Henseleit, U., Steinbrink, K., Sunderkotter, C., Goebeler, M., Roth, J., and Sorg, C. (1995) Expression of murine VCAM-1 in vitro and in different models of inflammation in vivo: correlation with immigration of monocytes. Exp. Dermatol. 4, 249-256
31. Wong, M. L., and Medrano, J. F. (2005) Real-time PCR for mRNA quantitation. BioTechniques 39, 75-85
32. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., and Speleman, F. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. [Online] Genome Biol. 3, Research0034
33. Elberg, G., Elberg, D., Logan, C. J., Chen, L., and Turman, M. A. (2006) Limitations of commonly used internal controls for real-time RT-PCR analysis of renal epithelial-mesenchymal cell transition. Nephron Exp. Nephrol. 102, e113-e122 (Pubitemid 43289536)
34. Malliaros, J., Holdsworth, S. R., Wojta, J., Erlich, J., and Tipping, P. G. (1993) Glomerular fibrinolytic activity in anti-GBM glomerulonephritis in rabbits. Kidney Int. 44, 557-564 (Pubitemid 23265224)
35. Huang, Y., Border, W. A., Lawrence, D. A., and Noble, N. A. (2009) Mechanisms underlying the anti-fibrotic properties of non-inhibitory PAI-1 (PAI-1R) in experimental nephritis. Am. J. Physiol. Renal Physiol 297, F1045-F1054
36. Falk, R. J., Podack, E., Dalmasso, A. P., and Jennette, J. C. (1987) Localization of S protein and its relationship to the membrane attack complex of complement in renal tissue. Am. J. Pathol. 127, 182-190 (Pubitemid 17062600)
37. Okada, M., Yoshioka, K., Takemura, T., Akano, N., Aya, N., Murakami, K., and Maki, S. (1993) Immunohistochemical localization of C3d fragment of complement and S-protein (vitronectin) in normal and diseased human kidneys: association with the C5b-9 complex and vitronectin receptor. Virchows Arch. A Pathol. Anat. Histopathol. 422, 367-373 (Pubitemid 23197351)
38. Ogawa, T., Yorioka, N., and Yamakido, M. (1994) Immunohistochemical studies of vitronectin, C5b-9, and vitronectin receptor in membranous nephropathy. Nephron Exp. Nephrol. 68, 87-96 (Pubitemid 24251194)
39. Wetsel, R. A., Fleischer, D. T., and Haviland, D. L. (1990) Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5′-exon. J. Biol. Chem. 265, 2435-2440
40. Van Dijk, H., Rademaker, P. M., and Willers, J. M. (1980) Determination of alternative pathway of complement activity in mouse serum using rabbit erythrocytes. J. Immunol. Methods 36, 29-39 (Pubitemid 10043212)
41. Osmers, I., Szalai, A. J., Tenner, A. J., and Barnum, S. R. (2006) Complement in BuB/BnJ mice revisited: serum C3 levels and complement opsonic activity are not elevated. Mol. Immunol. 43, 1722-1725
42. Xie, C., Sharma, R., Wang, H., Zhou, X. J., and Mohan, C. (2004) Strain distribution pattern of susceptibility to immunemediated nephritis. J. Immunol. 172, 5047-5055 (Pubitemid 38456432)
43. Seiffert, D., Keeton, M., Eguchi, Y., Sawdey, M., and Loskutoff, D. J. (1991) Detection of vitronectin mRNA in tissues and cells of the mouse. Proc. Natl. Acad. Sci. U. S. A. 88, 9402-9406 (Pubitemid 21915639)
44. Seiffert, D., Crain, K., Wagner, N., and Loskutoff, D. (1994) Vitronectin gene expression in vivo. Evidence for extrahepatic synthesis and acute phase regulation. J. Biol. Chem. 269, 19836-19842
45. Grandaliano, G., Gesualdo, L., Ranieri, E., Monno, R., and Schena, F. P. (2000) Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis. Am. J. Kidney Dis. 35, 726-738 (Pubitemid 30185520)
46. Loskutoff, D. J., Sawdey, M., Keeton, M., and Schneiderman, J. (1993) Regulation of PAI-1 gene expression in vivo. Thromb. Haemost. 70, 135-137 (Pubitemid 23225465)
47. Farrehi, P. M., Ozaki, C. K., Carmeliet, P., and Fay, W. P. (1998) Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 97, 1002-1008 (Pubitemid 28125473)
48. Preissner, K. T., and Jenne, D. (1991) Structure of vitronectin and its biological role in haemostasis. Thromb. Haemost. 66, 123-132